


Amendments to the Claims:

Please rewrite the claims as follows:


1. (Original) A drug delivery ophthalmic lens comprising a cationic group-containing drug in the inside of a copolymer consisting of a hydrophilic monomer having a hydroxyl group in its molecule, at least one member selected from phosphate group-containing methacrylates represented by the following structural formula (I), a monomer having a nitrogen atom in its side chain, and a monomer copolymerizable with these components,

formulae (I)




2. (Original) The drug delivery ophthalmic lens according to claim 1, wherein a mixture of the following structural formulae (II) and (III) is used as the phosphate group-containing methacrylates:

formulae (II)



formulae(III)



3. (Currently Amended) The drug delivery ophthalmic lens according to claim 1 ~~or 2~~, wherein the content of the monomer having a nitrogen atom in its side chain is 0.05 to 40 wt%.

4. (Currently Amended) The drug delivery ophthalmic lens according to ~~any one of claims 1 to 3~~ claim 1, wherein the monomer having a nitrogen atom in its side chain is (meth)acrylamide.

5. (Currently Amended) The drug delivery ophthalmic lens according to ~~any one of claims 1 to 4~~ claim 1, wherein the cationic group-containing drug is an organic compound having at least one quaternary ammonium base or primary to tertiary amine base in its molecule.

6. (Original) A drug delivery ophthalmic lens comprising an anionic group-containing drug in the inside of a copolymer consisting of a hydrophilic monomer, cationic and anionic monomers, and a monomer copolymerizable with these components, wherein the copolymer contains the anionic monomer in a ratio of 30 to 90 mol% to the cationic monomer.

7. (Original) The drug delivery ophthalmic lens according to claim 6, wherein the anionic group-containing drug is an organic compound having at least one member selected from a carboxyl group, a sulfo group and a phosphate group in its molecule.

8. (Currently Amended) A solution for storing the drug delivery ophthalmic lens according to ~~any one of claims 1 to 7~~ claim 6, which comprises a nonionic surfactant and a nonionic osmotic pressure regulating agent and is free of an ionic compound.

9. (Original) The storing solution according to claim 8, wherein the nonionic surfactant is a polyoxyethylene/polyoxypropylene nonionic surfactant (poloxamer type).

10. (Currently Amended) The storing solution according to claim 8 ~~or 9~~, wherein the nonionic osmotic pressure regulating agent is propylene glycol or glycerin.